The Recent Wave of Approval in AML

The Recent Wave of Approval in AML

obr

7 months
139 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School discusses the recent wave of approvals in AML and how it has changed treatment planning for patients.
Up Next Autoplay
Are Racial Disparities in AML Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Are Racial Disparities in AML Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Category: Acute Myelogenous Leukemia
20 Views
ash 1 month
Survivors of AML Treated with Blood or Marrow Transplantation #ASH19 @cityofhope
Survivors of AML Treated with Blood or Marrow Transplantation #ASH19 @cityofhope
Category: Acute Myelogenous Leukemia
13 Views
ash 1 month
Personalized Prediction Model to Risk Stratify Patients with AML Using AI #ASH19
Personalized Prediction Model to Risk Stratify Patients with AML Using AI #ASH19
Category: Acute Myelogenous Leukemia
17 Views
ash 1 month
Therapy for Secondary and Relapsed/ Refractory AML #ASH19 @RoswellPark
Therapy for Secondary and Relapsed/ Refractory AML #ASH19 @RoswellPark
Category: Acute Myelogenous Leukemia
34 Views
ash 1 month
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Category: Acute Myelogenous Leukemia
8 Views
Cancer-News 1 month
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
12 Views
Cancer-News 1 month
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Category: Acute Myelogenous Leukemia
44 Views
Cancer-News 2 months
How to Manage MDS Patients who are Ineligible for Transplant
How to Manage MDS Patients who are Ineligible for Transplant
Category: Acute Myelogenous Leukemia
304 Views
obr 7 months
Updated Data on Gilteritinib in AML
Updated Data on Gilteritinib in AML
Category: Acute Myelogenous Leukemia
19 Views
obr 7 months